Advertisement

Topics

Merck’s Keytruda meets survival challenge in NSCLC

07:24 EDT 17 Apr 2018 | PMLIVE

Data showed that almost 70% of patients on the combo were still alive after 12 months

Original Article: Merck’s Keytruda meets survival challenge in NSCLC

NEXT ARTICLE

More From BioPortfolio on "Merck’s Keytruda meets survival challenge in NSCLC"

Advertisement
Quick Search
Advertisement
Advertisement